Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Small cells – big issues : biological implications and preclinical advancements in small cell lung cancer

Solta, Anna ; Ernhofer, Büsra ; Boettiger, Kristiina ; Megyesfalvi, Zsolt ; Heeke, Simon ; Hoda, Mir Alireza ; Lang, Christian ; Aigner, Clemens ; Hirsch, Fred R. and Schelch, Karin , et al. (2024) In Molecular Cancer 23(1).
Abstract

Current treatment guidelines refer to small cell lung cancer (SCLC), one of the deadliest human malignancies, as a homogeneous disease. Accordingly, SCLC therapy comprises chemoradiation with or without immunotherapy. Meanwhile, recent studies have made significant advances in subclassifying SCLC based on the elevated expression of the transcription factors ASCL1, NEUROD1, and POU2F3, as well as on certain inflammatory characteristics. The role of the transcription regulator YAP1 in defining a unique SCLC subset remains to be established. Although preclinical analyses have described numerous subtype-specific characteristics and vulnerabilities, the so far non-existing clinical subtype distinction may be a contributor to negative... (More)

Current treatment guidelines refer to small cell lung cancer (SCLC), one of the deadliest human malignancies, as a homogeneous disease. Accordingly, SCLC therapy comprises chemoradiation with or without immunotherapy. Meanwhile, recent studies have made significant advances in subclassifying SCLC based on the elevated expression of the transcription factors ASCL1, NEUROD1, and POU2F3, as well as on certain inflammatory characteristics. The role of the transcription regulator YAP1 in defining a unique SCLC subset remains to be established. Although preclinical analyses have described numerous subtype-specific characteristics and vulnerabilities, the so far non-existing clinical subtype distinction may be a contributor to negative clinical trial outcomes. This comprehensive review aims to provide a framework for the development of novel personalized therapeutic approaches by compiling the most recent discoveries achieved by preclinical SCLC research. We highlight the challenges faced due to limited access to patient material as well as the advances accomplished by implementing state-of-the-art models and methodologies.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Molecular subtypes, Preclinical models, Small cell lung cancer, Translational progress
in
Molecular Cancer
volume
23
issue
1
article number
41
publisher
BioMed Central (BMC)
external identifiers
  • pmid:38395864
  • scopus:85185901886
ISSN
1476-4598
DOI
10.1186/s12943-024-01953-9
language
English
LU publication?
yes
id
607a8f39-e29b-41d5-aeb5-a6a93ba9028a
date added to LUP
2024-03-15 10:14:36
date last changed
2024-04-12 04:36:36
@article{607a8f39-e29b-41d5-aeb5-a6a93ba9028a,
  abstract     = {{<p>Current treatment guidelines refer to small cell lung cancer (SCLC), one of the deadliest human malignancies, as a homogeneous disease. Accordingly, SCLC therapy comprises chemoradiation with or without immunotherapy. Meanwhile, recent studies have made significant advances in subclassifying SCLC based on the elevated expression of the transcription factors ASCL1, NEUROD1, and POU2F3, as well as on certain inflammatory characteristics. The role of the transcription regulator YAP1 in defining a unique SCLC subset remains to be established. Although preclinical analyses have described numerous subtype-specific characteristics and vulnerabilities, the so far non-existing clinical subtype distinction may be a contributor to negative clinical trial outcomes. This comprehensive review aims to provide a framework for the development of novel personalized therapeutic approaches by compiling the most recent discoveries achieved by preclinical SCLC research. We highlight the challenges faced due to limited access to patient material as well as the advances accomplished by implementing state-of-the-art models and methodologies.</p>}},
  author       = {{Solta, Anna and Ernhofer, Büsra and Boettiger, Kristiina and Megyesfalvi, Zsolt and Heeke, Simon and Hoda, Mir Alireza and Lang, Christian and Aigner, Clemens and Hirsch, Fred R. and Schelch, Karin and Döme, Balazs}},
  issn         = {{1476-4598}},
  keywords     = {{Molecular subtypes; Preclinical models; Small cell lung cancer; Translational progress}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{Molecular Cancer}},
  title        = {{Small cells – big issues : biological implications and preclinical advancements in small cell lung cancer}},
  url          = {{http://dx.doi.org/10.1186/s12943-024-01953-9}},
  doi          = {{10.1186/s12943-024-01953-9}},
  volume       = {{23}},
  year         = {{2024}},
}